Gang, M.; Othus, M.; Olix, A.-C.; Markey, K.A.; Stirewalt, D.L.; Connelly-Smith, L.S.; Lee, S.J.; Milano, F.; Walter, R.B.
CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia. Cancers 2025, 17, 2323.
https://doi.org/10.3390/cancers17142323
AMA Style
Gang M, Othus M, Olix A-C, Markey KA, Stirewalt DL, Connelly-Smith LS, Lee SJ, Milano F, Walter RB.
CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia. Cancers. 2025; 17(14):2323.
https://doi.org/10.3390/cancers17142323
Chicago/Turabian Style
Gang, Margery, Megan Othus, Anne-Chloe Olix, Kate A. Markey, Derek L. Stirewalt, Laura S. Connelly-Smith, Stephanie J. Lee, Filippo Milano, and Roland B. Walter.
2025. "CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia" Cancers 17, no. 14: 2323.
https://doi.org/10.3390/cancers17142323
APA Style
Gang, M., Othus, M., Olix, A.-C., Markey, K. A., Stirewalt, D. L., Connelly-Smith, L. S., Lee, S. J., Milano, F., & Walter, R. B.
(2025). CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid Leukemia. Cancers, 17(14), 2323.
https://doi.org/10.3390/cancers17142323
